Mayo Clinic Hemophilia Treatment
Center and 340B Program
Jenni Hovell, CPA, MHA
Operations Manager—Mayo Clinic Midwest 340B Programs
Hemophilia Alliance Spring Meeting
April 27, 2015
©2015 MFMER | slide-1
Mayo Clinic
• Major Campuses in Minnesota
(Rochester), Arizona (Scottsdale &
Phoenix) and Florida (Jacksonville)
• Mayo Clinic Health System Campuses
in Minnesota, Iowa, Wisconsin, and
Georgia
• Personnel across all campuses
• 4,100 staff physicians & scientists
• 3,100 residents, fellows, &
students
• 52,100 Allied health staff
• Patients across all campuses
• 1,260,000 clinic patients
• 131,000 hospital admissions
• 608,000 patient hospital days
©2015 MFMER | slide-2
©2015 MFMER | slide-3
HTC Roll-up Structure
Mayo Clinic Board of Governors
Midwest Executive Operating Team
Midwest Specialty Care Clinical Practice Committee
Department of Medicine
Hematology
Hemophilia Treatment Center
©2015 MFMER | slide-4
HTC Staff
• Dr. Rajiv Pruthi, HTC Medical Director (since
2000)
• 11 Physicians in Coagulation interest group
• 3 RN Care Coordinators
• Social Worker
• Genetics Counselor
• Physical Therapist
• Medical Secretary
©2015 MFMER | slide-5
HTC History
• 1971—established HTC under the direction of Drs Bowie, Gilchrist, and Hagedorn
• Established an outpatient program providing replacement therapy (single-donor
cryo)
• Began instructing patients on home product storage, preparation, and infusion
techniques
• 1972—designation as an International Hemophilia Training Center
• 1976—addition of a nurse care coordinator and social worker to the clinical team
• 1986—began offering formal genetic counseling and DNA testing to patients
• 1990—Dr. Dennis Gastineau becomes HTC co-Director with Dr. Gilchrist
• 1991—first annual Minnesota Hemophilia Camp
• 1995—made it policy to recommend recombinant-derived factor as first choice for all
factor replacement therapy patients
• 2000—Dr. Rajiv Pruthi named HTC Medical Director
• 2006—340B program started
©2015 MFMER | slide-6
HTC Patients
• 264 total bleeding disorder patients
• 87 Hemophilia A
• 24 Hemophilia B
• 100 vonWillebrand Disease
• 26 Other factor deficiencies
• 27 Other bleeding disorders
• 57% male, 43% female
• 21% pediatrics
©2015 MFMER | slide-7
HTC Patient Support Services
• Patient education weekend
• School in-services
• Self-infusion classes
• Women’s retreat
• Patient transportation
• Quality projects to benefit patient care
• Support of the Hemophilia Foundation of
Minnesota/Dakotas
©2015 MFMER | slide-8
HTC 340B Program
• Started in 2006
• Used contract pharmacy arrangement to
service patients
• Maintained a very small patient group on
service
• Bringing services in-house to our Mayo
Specialty Pharmacy
• Potential to grow patients on service
©2015 MFMER | slide-9
340B at Mayo Clinic
• Many different Covered Entity types
• Comprehensive Hemophilia Treatment
Center
• Ryan White Part B Grantee
• Disproportionate Share Hospital
• Critical Access Hospital
• Sole Community Hospital
• Entities across the Midwest
• Minnesota (MCHS sites and Rochester)
• Wisconsin (MCHS sites)
©2015 MFMER | slide-10
340B Operations Manager Role
• Fall 2013 asked for an Operations Manager for
HTC 340B
• Spring 2014 Business Plan for all Midwest 340B
developed
• Midwest 340B Operations Manager hired June
2014
• Responsibilities
• 50% Midwest Subcommittee
• 25% HTC
• 25% HIV
©2015 MFMER | slide-11
340B Oversight Subcommittee
©2015 MFMER | slide-12
Authorizing Official Role
• CAH, SCH, DSH have requirement that
Authorizing Official is C-level or VP
• HTC and HIV Authorizing Official was Chair of
the Legal Department
• Wanted someone closer to the program
• Granted Designation of Signing Authority to our
Midwest 340B Medical Director for Certification
of 340B Programs on Rochester campus
©2015 MFMER | slide-13
Questions
©2015 MFMER | slide-14